Farnesoid X Receptor an Emerging Target to Combat Obesity.

Journal: Dig Dis

Publication Year: 2017

Authors: C Daniel De Magalhaes Filho, Michael Downes, Ronald M Evans

PubMed link: 28249279

Funding Grants: Molecular Characterization and Functional Exploration of Nuclear Receptors in hiPSCs, Metabolically-driven epigenetic changes in iPSC reprogramming

Public Summary:
Obesity and its associated diseases, including type 2 diabetes, have reached epidemic levels worldwide. However, available treatment options are limited and ineffective in managing the disease. There is therefore an urgent need for the development of new pharmacological solutions. The bile acid (BA) Farnesoid X receptor (FXR) has recently emerged as an attractive candidate. Initially described for their role in lipid and vitamin absorption from diet, BAs are hormones with powerful effects on whole body lipid and glucose metabolism. In this review, we focus on FXR and how 2 decades of work on this receptor, both in rodents and humans, have led to the development of drug agonists with potential use in humans for treatment of conditions ranging from obesity-associated diseases to BA dysregulation.

Scientific Abstract:
Obesity and its associated diseases, including type 2 diabetes, have reached epidemic levels worldwide. However, available treatment options are limited and ineffective in managing the disease. There is therefore an urgent need for the development of new pharmacological solutions. The bile acid (BA) Farnesoid X receptor (FXR) has recently emerged as an attractive candidate. Initially described for their role in lipid and vitamin absorption from diet, BAs are hormones with powerful effects on whole body lipid and glucose metabolism. In this review, we focus on FXR and how 2 decades of work on this receptor, both in rodents and humans, have led to the development of drug agonists with potential use in humans for treatment of conditions ranging from obesity-associated diseases to BA dysregulation.

Source URL: https://www.cirm.ca.gov/about-cirm/publications/farnesoid-x-receptor-emerging-target-combat-obesity